SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members discuss potential catalysts related to reshoring chip manufacturing and government support, possibly including mandates. Optimism is fueled by reported interest from major tech players and significant investment, with some speculating about a potential return to previous highs and beyond. Community members are actively debating the sustainability of the rally and the impact of government policies.

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Indaptus Therapeutics Inc

INDP is trending due to a potential short squeeze, fueled by a low float and high cost to borrow, leading to significant price volatility and trading halts. The community is actively discussing potential price targets and the possibility of a substantial run, while closely monitoring short positions. Some traders are drawing comparisons to other stocks with similar dynamics, hoping for comparable gains.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors discuss its potential to break through the $54.50 resistance level, with some citing bullish call flow and projecting a climb to $60 or higher by the end of the year. Community members are actively monitoring volume and chart patterns, while also referencing articles that support a positive outlook for the stock and its sector. Some traders believe the recent acquisition of Alani Nu and overall growth will drive the price up significantly before the next earnings report.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to positive analyst coverage and increasing optimism around its AI cloud scaling potential, with the community discussing price targets and the possibility of a short squeeze. Bullish investors believe IREN is undervalued and poised for significant growth, while others express concern about its valuation and potential pullback. Discussions also involve comparisons to peers like CIFR and NBIS, and speculation about future deals and market dynamics.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies is trending due to recent case studies showcasing the effectiveness of its CyPath Lung test in early lung cancer detection, potentially reducing the need for invasive procedures. The community is actively discussing the company's fresh story and the potential for a significant upside given its low float. Some traders are setting high price targets while others are cautious about possible dilution.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a recent multi-billion dollar AI compute deal, with community members actively discussing the financial backing from Google and the potential impact on shareholder value. Despite positive news, the stock experienced a sell-off, leading to debates around market manipulation, dilution concerns, and future price targets. Some investors view the dip as a buying opportunity, citing the company's strategic shift towards high-performance computing and long-term growth potential in the AI sector.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as anticipation builds for a major announcement expected on Monday, sparking community speculation about a potential "Model T moment" related to EVs. The community is actively discussing the potential impact of this announcement, with some expressing skepticism given the company's history and others suggesting partnerships or product innovations may be unveiled. Broader market factors, such as tariffs and potential impact on EVs, are also part of the conversation.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak ($KODK) is trending amid community discussion around its pharmaceutical manufacturing capabilities and potential benefits from new pharmaceutical tariffs.  Some investors are optimistic about a short squeeze due to high short interest, while others express skepticism based on past performance. The community is actively monitoring for news related to government contracts and the finalization of pension assets.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to potential government funding shifts and their impact on the company's strategic rare-earth supply program, a key national security priority. The community is debating the validity of rumors about Congress pulling funding and analyzing the potential for both short-term volatility and long-term growth catalysts. Bullish sentiment remains, fueled by the company's national security status and potential for increased magnet demand.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending as community members discuss the potential for a breakout, buoyed by a Morgan Stanley buy rating and target price. Traders are weighing the possibility of a short squeeze amid observations of steady price levels and biotech sector momentum. Attention is also focused on the company's recent FDA approval and upcoming availability of Palsonify, with some analysts raising price targets significantly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy

Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.

Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience

Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.

CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU

CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.

5 Biotech Stocks Worth Adding to Your Portfolio Now 

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update

KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Akero Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$47.09
Prev Close	$46.22
Open	$46.10
Dividend Yield	0.00%
50-Day Moving Average	$47.73
Beta	0.94
Avg. Volume	987,639.38
PE Ratio	-12.16

52-Week High	$58.40
52-Week Low	$21.34
Market Capitalization	$3.7B
EPS (Annual)	-$3.75
Price to Book	3.60
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AKRO
Akero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKRO News

AKRO Akero Therapeutics Inc